Quebec is preparing to experience significant changes in its public drug insurance plan from July 1, 2024, with a reduction in the deductible and co-insurance, thus allowing a reduction in the financial burden for policyholders during the purchase of prescribed medications.
The Régie de l’assurance santé du Québec (RAMQ) announced that these price adjustments would extend until June 30, 2025, aiming to improve accessibility to drug treatments.
The annual premium will increase slightly, from $731 to $744, representing an increase of 1.8%. This price change is the result of a new agreement with the Canadian Generic Pharmaceutical Association and the introduction of biosimilar drugs which generated substantial savings. These savings have helped reduce inflationary pressures on drug costs, thereby reducing costs for policyholders.
In terms of pharmacy contributions, policyholders will benefit from a reduction in the monthly deductible which will go from $22.90 to $22.00 and a reduction in co-insurance, now set at 32% compared to 33% previously. The maximum monthly contribution remains unchanged at $99.65 for members and people aged 65 or over who do not receive the Guaranteed Income Supplement (GIS), and at $56.17 for those receiving the GIS.
This plan, unique in Canada, insures more than 3.9 million people, 33% of whom pay no annual premium and 21% benefit from completely free medications. It aims to provide basic protection against the costs of pharmaceutical services and medicines, taking into account the economic situation of beneficiaries.
These changes reflect Quebec’s commitment to providing equitable and reasonable access to necessary medications, thereby strengthening the general well-being of its population. For more information, consult the RAMQ website at ramq.gouv.qc.ca.
Source: Régie de l’assurance santé du Québec / CNW
Health Index Publication: 2024-06-27
Number of visits since publication: 8
To read on Health Index:
